Pharmaceuticals company Indoco Remedies announced Q2FY26 results Revenues of Rs 4,293 million, as against Rs 3,946 million, in Q2FY25, registering an 8.8 % revenue growth. EBIDTA for the quarter is at Rs 534 million, compared to Rs 529 million in Q2FY25. PBT: Rs 97.6 million compared to Rs 173.8 million during Q2FY25. PAT: Rs 150.5 million compared to Rs 127.9 million during Q2FY25. Aditi Panandikar, Managing Director, Indoco Remedies, said: “International formulation and API businesses had a good growth this quarter. The India formulation business performance was impacted due to revision in the GST rates. We are confident of regaining momentum in the coming quarters.” Result PDF